The effect of ß-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism

Summary

High factor VIII (FVIII) is a risk factor for venous thromboembolism (VTE). The pathomechanism by which high FVIII leads to an increased risk of VTE is unknown. Physical activity and infusion of adrenalin provoke a rise in FVIII, which can be blocked by a nonselective β-blockade. We tested the hypothesis that in patients with a VTE β-blockade decreases FVIII and inhibits coagulation activation.

17 male patients with high FVIII (> 170 IU/dL, n = 7) or low FVIII (<150 IU/dL, n = 10) and a history of VTE received 40 mg of propranolol thrice daily for 14 days. FVIII and vasopressin levels were measured before and during propranolol intake and 28 days thereafter. At the same time points, haemostatic system activation was investigated by measuring prothrombin fragment f1.2 (f1.2) and thrombin antithrombin complexes (TAT) in venous blood and in blood emerging from a skin incision (shed blood).

The mean FVIII level before propranolol was 192 IU/dL and 115 IU/dL in patients with high and low FVIII, respectively. During and 28 days after propranolol, no significant change in FVIII was seen in both groups. Changes in f1.2 and TAT were not detectable in either venous blood or in shed blood.

β-receptor blockade did not lower FVIII or inhibit haemostatic system activation in patients with VTE and persistently high FVIII. Administration of propranolol cannot be recommended as secondary thromboprophylaxis in patients with high FVIII.

Keywords

Venous thrombosis - factor VIII - ß-receptor blockade - thrombin generation

• References

• 1 Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR.. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-5.
• 2 O’Donnell J, Tuddenham EG, Manning R, Kemball-Cook G, Johnson D, Laffan M.. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 1997; 77: 825-8.
• 3 O’Donnell J, Mumford AD, Manning RA, Laffan M.. Elevation of FVIII: C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-3.
• 4 Kyrle PA, Minar E, Hirschl M.. et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
• 5 Kraaijenhagen RA, in’t-Anker PS, Koopman MM.. et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
• 6 Kamphuisen PW, Eikenboom JCJ, Vos HL.. et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reaction. Thromb Haemost 1999; 81: 680-3.
• 7 Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS.. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998; 279: 458-62.
• 8 Levine MN, Raskob G, Landefeld S, Kearon C.. Hemorrhagic complications of anticoagulant treatment. Chest 1998; 114: 511S-23S.
• 9 Small M, Tweddel AC, Rankin AC, Lowe GD, Prentice CR, Forbes CD.. Blood coagulation and platelet function following maximal exercise: effects of beta-adrenoceptor blockade. Haemostasis 1984; 14: 262-8.
• 10 Mannucci PM, Aberg M, Nilsson IM, Robertson B.. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs. Br J Haematol 1975; 30: 81-93.
• 11 Mannucci PM.. Enhancement of plasminogen activator by vasopressin and adrenaline: a role of cyclic AMP?. Thromb Res 1974; 4: 539-49.
• 12 Cohen RJ, Epstein SE, Cohen LS, Dennis LH.. Alterations of fibrinolysis and blood coagulation induced by exercise, and the role of beta-adrenergic-receptor stimulation. Lancet 1968; 2: 1264-6.
• 13 Kraaijenhagen RA, Hoppener MR, Levi M, Büller HR.. Beta-receptor blockade decreases elevated plasma levels of factor VIIIc in patients with deep vein thrombosis. The etiology of this important risk factor revealed?. Blood 2000; 96: 450a.
• 14 Mielke C-HJ, Kaneshiro MM, Maher IA, Weiner JM, Rapaport SI.. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood 1969; 34: 204-15.
• 15 Bauer KA, Barzegar S, Rosenberg RD.. Influence of anticoagulants used for blood collection on plasma prothrombin fragment F1 + 2 measurements. Thromb Res 1991; 63: 617-28.
• 16 Mannucci PM, Tripodi A, Bottasso B.. et al. Markers of procoagulant imbalance in patients with inherited thrombophilic syndromes. Thromb Haemost 1992; 67: 200-2.
• 17 Zoller B, Holm J, Svensson P, Dahlback B.. Elevated levels of prothrombin activation fragment 1 + 2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
• 18 Simioni P, Scarano L, Gavasso S.. et al. Prothrombin fragment 1+2 and thrombinantithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
• 19 Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM.. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
• 20 Kyrle PA, Eichinger S, Pabinger I.. et al. Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism. Thromb Haemost 1997; 77: 829-33.
• 21 O’Donnell J, Mumford AD, Manning RA, Laffan MA.. Marked elevation of thrombin generation in patients with elevated FVIII: C and venous thromboembolism. Br J Haematol 2001; 115: 687-91.
• 22 Eichinger S, Wolzt M, Schneider B.. et al. Effects of recombinant hirudin (r-hirudin, HBW 023) on coagulation and platelet activation in vivo. Comparison with unfractionated heparin and a low-molecular-weight heparin preparation (fragmin). Arterioscler Thromb Vasc Biol 1995; 15: 886-92.
• 23 Eichinger S, Wolz M, Nieszpaur-Los M.. et al. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo. Thromb Haemost 1994; 72: 831-5.